In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
You may also be interested in...
GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary
GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.
Eisai Brings Halaven To India With A Tiered-Pricing Strategy
The Japanese drug firm is making a strong bid to make expensive drugs affordable in emerging markets like India. For those who cannot pay, the drug will be made available free of charge.
GSK India Saves Tykerb Main Patent But Loses Claims On Salt Patent To Fresenius Kabi
Amid a series of patent related setbacks faced by global drug firms, GSK has safeguarded Tykerb against Fresenius Kabi.